Design Therapeutics (DSGN) Projected to Post Earnings on Thursday

Design Therapeutics (NASDAQ:DSGN) is expected to be posting its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter. Parties may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Friday, November 14, 2025 at 4:00 PM ET.

Design Therapeutics (NASDAQ:DSGN) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.02). On average, analysts expect Design Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Design Therapeutics Trading Down 4.7%

Shares of DSGN stock opened at $6.24 on Wednesday. The stock has a market capitalization of $355.36 million, a price-to-earnings ratio of -5.57 and a beta of 1.67. Design Therapeutics has a 12-month low of $2.60 and a 12-month high of $7.77. The stock’s 50-day moving average price is $6.23 and its 200-day moving average price is $4.83.

Hedge Funds Weigh In On Design Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Bridgeway Capital Management LLC raised its holdings in Design Therapeutics by 65.4% during the 2nd quarter. Bridgeway Capital Management LLC now owns 188,200 shares of the company’s stock valued at $634,000 after buying an additional 74,400 shares during the period. Bank of America Corp DE increased its position in Design Therapeutics by 11.1% during the second quarter. Bank of America Corp DE now owns 24,625 shares of the company’s stock valued at $83,000 after acquiring an additional 2,459 shares during the last quarter. Jane Street Group LLC increased its position in Design Therapeutics by 71.5% during the second quarter. Jane Street Group LLC now owns 31,079 shares of the company’s stock valued at $105,000 after acquiring an additional 12,954 shares during the last quarter. Invesco Ltd. raised its stake in shares of Design Therapeutics by 26.8% in the second quarter. Invesco Ltd. now owns 14,364 shares of the company’s stock valued at $48,000 after acquiring an additional 3,033 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of Design Therapeutics by 2.4% in the 2nd quarter. Geode Capital Management LLC now owns 794,008 shares of the company’s stock worth $2,676,000 after acquiring an additional 18,511 shares during the last quarter. Hedge funds and other institutional investors own 56.64% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Design Therapeutics in a report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.